Angiotech’s next frontier?
This article was originally published in The Gray Sheet
Executive Summary
High-volume orthopedics is the "next obvious place to go," President and CEO William Hunter says June 15 at Thomas Weisel Partners Growth Forum. Details of the firm's plan to "dip a toe" into the soft tissue market will be provided during the firm's analyst meeting June 24, Hunter noted. The Canadian drug company announced June 10 it has completed enrollment for the 60-patient European Vascular Wrap clinical trial six months ahead of schedule. An extra 20 patients have been added, and the study has been expanded from four to 12 sites...
You may also be interested in...
Alvotech Highlights Lack Of Simponi Rivals As It Delivers Golimumab Results
Alvotech has just become the first company to announce positive topline results from a confirmatory clinical study for a proposed golimumab rival to Simponi and Simponi Aria – and moreover, the firm sees limited competition from other biosimilars on the horizon.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.